An observational study in Sepsis, Device Performance and Emergency Medicine, sponsored by Intermountain Health Care, Inc.. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Intermountain Health Care, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 517 studies in Sepsis with a site in United States — 74 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.
Among the 517 studies in Sepsis with a site in United States, this one is the 12th largest by planned enrollment of the 204 observational ones that give a count, is one of 21 that started in 2025, is one of 204 observational ones, reaches primary completion later than 26 of the 98 other live ones, and was the 496th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →74 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:
Deepull Diagnostics S.L. · Sites in United States, France, Germany and 2 more countries
Intermountain Health Care, Inc. · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 0 days–7 days
Vanderbilt University Medical Center · Sites in United States
Ages 1 days–12 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
517 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 80 · Phase 3 47 · Phase 4 25
First in 1988; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 84 across the 310 interventional studies, 183 across the 204 observational. Of the 361 that completed or were terminated, 117 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
135 of 517 have an industry lead sponsor. The 10 most frequent:
Intermountain Health Care, Inc. is the lead sponsor of 120 studies on the registry; 15 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 3 (33%) have results posted.
Intermountain Health Care, Inc. has 9 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
37 of the studies in Sepsis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06817408Mayo ClinicDynamics of Organ Damage and Immune Exhaustion During Sepsis | 2026-12 |
| NCT04796285Brigham and Women's HospitalA Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor | 2026-12 |
| NCT01315782The University of Texas Health Science Center, HoustonAlveolar Dead Space as Predictor of Organ Failure in Severe Sepsis | 2026-12 |
| NCT06692400Loma Linda UniversityThe Effects of Endotracheal Suctioning on Pain and Serum Markers | 2026-12 |
| NCT03133208University of FloridaSepsis Associated Encephalopathy (SAE) Biomarkers | 2026-12-15 |
Add all 37 to your calendar (.ics) → With an account.
Among the 517 studies in Sepsis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators will implement a protocol for use of the PIVO device for blood culture collection in the emergency department. This protocol utilizes the device in various scenarios to reduce needlesticks while allowing for accurate and appropriate assessment of potential pathogens in the bloodstream. The study team will train staff on use of the device then monitor utilization and contamination rates among emergency department patients.
This prospective implementation and efficacy study will be conducted with primary implementation at three Intermountain Health emergency departments: Park City Hospital (Park City, Utah), Primary Children's Hospital (Salt Lake City, Utah), and Utah Valley Hospital (Provo, Utah). These three sites have a combined annual emergency department visit volume exceeding 100,000 visits, ensuring a robust implementation setting for the evaluation of blood culture practices. The investigators will seek to expand the protocol to three secondary sites, pending the results of the initial data regarding blood culture contamination rates from the primary sites. These secondary sites include the emergency departments at Intermountain Medical Center (Murray, Utah). LDS Hospital (Salt Lake City, Utah), and McKay-Dee Hospital (Ogden Utah). These sites have combined annual emergency department volumes exceeding 150,000 patients per year.
The study will launch on October 1, 2025, following the system-wide Epic EHR deployment in September 2025. During October, each ED will undergo a structured training program for clinical staff, including ED nurses, physicians, and phlebotomists. This training will focus on the indications for PIVO use, technical instructions, workflow integration, and documentation standards within Epic. After training, the PIVO protocol will be implemented for a total study duration of 13 months, with data collection occurring between November 2025 and October 2026. The investigators will perform interim analyses at three, six, and nine months to assess PIVO utilization and any need for site-specific re-training, feedback, and intervention. The study team will perform a REDCap-based survey of relevant practitioners (phlebotomists, laboratory technicians, and nurses) who have utilized the device at ten months to assess their comfort with use and willingness to recommend the device. All individuals who have performed at least one blood culture draw utilizing the PIVO will be eligible to participate. The study team will distribute the survey link through site clinical leaders to relevant groups who perform these draws, and they will be asked to participate if they have utilized the PIVO. Investigators will obtain informed consent for participation per Intermountain IRB procedures.
After the review of blood culture results and contamination rates at three months, as well as feedback from the primary site clinical leaders regarding the efficacy and ease of use of the PIVO, the study team will work with clinical leaders at the secondary sites of Intermountain Medical Center, LDS Hospital, and McKay-Dee Hospital to expand the protocol to these emergency departments. Currently, Intermountain Medical Center and LDS Hospital do not utilize the PIVO; the team will provide training and take necessary steps for implementation pending approval from clinical leaders within these sites. McKay-Dee Hospital is currently using the PIVO but will also likely require training specific to its use within this protocol in the emergency department setting. The investigators will aim to have implementation of the protocol within these sites at the six-month mark with ongoing data collection related to blood culture contamination rates across all sites over the entire study period.
Based on historical data and protocol-defined inclusion criteria, the investigators estimate that approximately 5,000 total blood cultures will be collected across the three primary EDs during the one-year study period. Pending adoption of the protocol at the secondary sites, the team would anticipate an additional 5,000 total blood cultures performed in these emergency departments over six months. The investigators anticipate that approximately 40% (4,000 blood cultures) will involve the PIVO device. The remaining 6,000 cultures will be collected via standard venipuncture practices. The investigators expect that for the large majority of the cultures obtained with the PIVO device, patients will have also had a blood culture performed using standard procedures.
The PIVO utilization protocol involves three scenarios. In all three scenarios, blood culture draws using PIVO will occur within 24 hours of IV placement, which is in line with the FDA approval for this indication and per guidance from the manufacturer (BD) regarding this approval.
To assess clinician satisfaction, a standardized survey tool will be administered to ED staff who use the PIVO device at the study's ten-month mark. The study will utilize the validated System Usability Scale survey with adjustments to reflect use of the PIVO device (see "Clinician Survey"). This tool will include 5-point Likert scale items evaluating: ease of use, comfort using the device, workflow impact, provider assessment of patient comfort, and likelihood of recommending the device to colleagues. The survey will be pilot tested with approximately ten clinicians to assess clarity and usability. Feedback from this pilot will inform revisions prior to wider deployment. For research purposes, all survey responses will be collected anonymously.
To assess contamination rates, all blood cultures will be classified as contaminated or non-contaminated utilizing Intermountain's current review process. For blood cultures classified as contaminated, two study investigators, blinded to collection method, will evaluate each case using Intermountain Health's standard contamination criteria, such as presence of skin flora in a single bottle without clinical indicators of infection. In ambiguous cases, adjudication will be supported by Infectious Disease consultation and reference to peer-reviewed criteria from the literature. In cases of disagreement between reviewers, a third reviewer will resolve the discrepancy.
The study will compare contamination rates in PIVO-collected cultures to those collected via standard methods. The benchmark contamination rate for Intermountain EDs is approximately 1.2%. To evaluate non-inferiority, the study team will use a margin of 0.8%. Based on our expected sample size (4,000 PIVO cultures, 6,000 standard cultures), the investigators estimate the study will have over 80% power to demonstrate that the PIVO group is non-inferior, provided the contamination rate does not exceed 2%. The research team will compare PIVO-related contamination rates to the contamination rates for non-PIVO cultures over the study period at the study sites and will perform a secondary analysis to compare contamination rates by facility.
The study team will perform interim analyses at three, six, and nine months to compare contamination rates between PIVO-obtained cultures and non-PIVO cultures across all included sites. The investigators will present this data to ED medical directors and laboratory leadership to either support the continued use of PIVO in their emergency departments or to discontinue its use (guided by statistical analysis demonstrating evidence of inferiority for blood culture contamination).
Data will be captured via Epic reporting tools, device usage logs, and manually adjudicated culture reviews. Variables will include: demographics (e.g., age, sex), culture method (PIVO vs. standard), success/failure of venipuncture, indication for PIVO use, microbiologic results (including contamination status), results of clinical testing, method and site of obtaining the blood culture, and survey responses from clinicians.
Statistical analysis will include descriptive statistics, proportions with 95% confidence intervals, and comparisons using chi-square or Fisher's exact tests. The study team will perform additional assessment of contamination rates using Newcombe and Miettinen scores with Nurminen confidence intervals around differences, comparing lower bounds to the non-inferiority margin. Subgroup analyses will be conducted by site and provider role. Final analysis and manuscript preparation will occur in October 2026 following full adjudication of all cultures.
This study evaluates patients in whom blood cultures are obtained in the emergency department during the study period. The primary population of interest is those in whom the PIVO device is used, with comparison to the overall population of patients in whom blood cultures are obtained.
Inclusion Criteria: Patients in whom blood cultures are obtained in the emergency department.
-
Exclusion Criteria: none
-
This cohort includes patients in whom PIVO is used to assess successful use of the device and contamination rates among blood cultures obtained.
Device: PIVO device, a needle-free blood draw device
This comparison group includes patients in whom the PIVO device is not used for comparison to blood cultures in which it is used.
The PIVO device, a needle-free blood draw device, may be used through an IV to obtain a blood sample and extends beyond the IV to ideally reduce the potential for contamination and to improve success in obtaining a sample. Per Google AI: "PIVO™ by Velano Vascular stands for Peripheral IV Origin, a needle-free blood draw device that uses a patient's existing peripheral IV (PIV) line to collect blood, avoiding extra needle sticks and reducing pain, hemolysis, and contamination, facilitating the "One-Stick Hospital Stay" goal for better patient care."
PIVO utilization
The investigators will assess utilization of the device for blood cultures obtained in the emergency department through review of the medical record and documentation of cases in which PIVO was used for blood cultures as a proportion of all blood cultures obtained.
Time frame: From baseline until 12 months after baseline
Contamination rates
The investigators will assess contamination rates for blood cultures obtained using the device compared to blood cultures obtained without the device.
Time frame: From baseline until 12 months after baseline
Staff satisfaction and willingness to recommend the device
The investigators will survey staff who have utilized the PIVO device to assess their satisfaction with use and willingness to recommend this to others.
Time frame: Six months after study initiation
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intermountain Health Care, Inc. →